Selective MRGPRX2 Modulators for Mast-Cell Activation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective modulators for Mas-related G-protein coupled receptor X2 (MRGPRX2) to treat conditions such as pseudo-allergic reactions, chronic itch, inflammation, pain, and autoimmune disorders, as these receptors are poorly understood and have limited orthologs in other species.
Innovation Solution
Development of modulator compounds that interact with MRGPRX2 as inverse agonists or competitive antagonists, selectively blocking ligand activation and reducing overactivity of MRGPRX2 in mast cells to treat conditions like pseudo-allergic reactions, itch, pain, and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MRGPRX2 modulators are developed to treat pseudo-allergic reactions and inflammation, then therapeutic effectiveness is improved, but the complexity of drug development increases due to limited knowledge about receptor function and lack of orthologs in other species
Solution Approach 1:
The patent develops modulator compounds that can selectively target MRGPRX2 receptors across multiple species (human, primate, dog, horse) despite limited ortholog knowledge. The compounds are designed to interact with conserved receptor structures to achieve broad therapeutic applicability for pseudo-allergic reactions, chronic itch, inflammation, and pain conditions while managing development complexity through targeted selective modulation
2Measurement precision
If modulator compounds are designed to selectively block MRGPRX2 activation, then specificity of treatment is improved, but the difficulty of compound design and screening increases due to poor understanding of receptor ligands
Solution Approach 1:
The patent employs structure-activity relationship (SAR) analysis to optimize modulator compounds, systematically varying molecular parameters to achieve selective MRGPRX2 modulation. The compounds are designed with specific structural features (e.g., aromatic rings, heterocyclic groups, substituent patterns) that enhance binding affinity and selectivity for MRGPRX2 over other receptors, addressing both specificity and screening challenges
Data Source
AI summary
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.